NRIX

Nurix Therapeutics, Inc. is a clinical-stage biotechnology company developing targeted protein degradation therapies for cancer and immune disorders. The company uses its proprietary DELigase platform to discover small molecules that harness the ubiquitin-proteasome system to degrade disease-causing proteins. Nurix has multiple drug candidates in clinical development targeting difficult-to-treat cancers and inflammatory diseases.